A new study by Médecins Sans Frontières (MSF) has found that 95 percent of children treated for tuberculosis (TB) in Uganda and the Philippines successfully completed treatment under a shorter four-month regimen, strengthening the case for wider adoption of the World Health Organization (WHO)-recommended treatment.
The findings, released on Tuesday, November 17, 2026, at the Union World Conference on Lung Health in Rio de Janeiro, Brazil, show that the shorter treatment can be successfully introduced in routine healthcare settings, reducing the time children spend on medication from six months to four months.
The study, which involved 214 children receiving care in health facilities in the two countries, found that 74 percent of the children were eligible for the shorter treatment at the beginning of therapy. Eligibility increased to 89 per cent among children assessed in primary healthcare settings.
MSF said the findings demonstrate that a substantial number of children diagnosed with TB could benefit from the shorter treatment, reducing the number of hospital visits, treatment-related costs and disruption to family life.
“Every three minutes, a child dies of TB. We cannot keep leaving children behind when effective medical tools are already within reach, including reducing treatment duration for children with non-severe TB from six months to four months,” said Dr Ana Paula Cavalheiro, Leader of MSF’s Global TB Platform.
She called on governments and donors to increase investment in early diagnosis and ensure children receive appropriate treatment regardless of where they live.
“It is high time governments and donors step up and ensure that children can be diagnosed early and receive the best possible treatment and care, no matter where they live,” Cavalheiro said.
The shorter regimen is designed for children with non-severe, drug-susceptible TB, meaning the disease has not caused extensive damage to the lungs or spread widely in the body and responds to standard first-line medicines.
Under WHO recommendations, the four-month treatment consists of two months of isoniazid, rifampicin and pyrazinamide, with or without ethambutol, followed by two months of isoniazid and rifampicin.
The treatment uses the same medicines as the standard six-month regimen but reduces the period children must take them. It is also available in child-friendly dispersible tablet formulations.
Despite WHO recommending the four-month regimen in 2022, its adoption has been slow in several countries with a high burden of tuberculosis, partly because health workers need to establish which children qualify for the shorter treatment.
Identifying eligible children requires clinical assessment and, where available, chest X-rays to determine the severity of the disease and whether the shorter treatment can safely be administered.
Valentina Carnimeo, Principal Investigator of the MSF multi-country TB study, said the shorter treatment would ease the burden on children, caregivers and healthcare systems without requiring a different combination of medicines.
“The four-month treatment regimen for children with non-severe, drug-susceptible TB uses the same medicines, including child-friendly formulations, but substantially reduces the burden on children and caregivers,” Carnimeo said.
She added that reducing treatment by two months would mean fewer clinic visits, lower expenses for families and health facilities, less disruption to family routines and fewer days of exposure to possible adverse effects of medication.
The study also found that healthcare workers and caregivers welcomed the shorter treatment because it reduced the demands associated with taking children for regular medical appointments.
However, MSF identified limited access to chest X-ray services, inadequate training of healthcare workers and high staff turnover as some of the challenges that could affect the wider implementation of the treatment.
Dr Maria Namulwana, Study Coordinator at MSF/Epicentre Uganda, said the experience in Uganda demonstrated that the shorter treatment could be introduced into existing healthcare programmes, but called for additional investment to ensure more children benefit.
“Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider roll-out,” Namulwana said.
She urged governments to strengthen healthcare workers’ training, improve access to diagnostic services, ensure the availability of child-friendly medicines and support families throughout the treatment period.
“But to make this a reality for more children, governments must go beyond updating guidelines and invest in training healthcare workers, strengthening diagnostic services, ensuring access to child-friendly medicines and supporting families throughout treatment,” she added.
MSF has been working to improve tuberculosis prevention, diagnosis and treatment among children in 12 countries through its Test, Avoid and Cure TB in Children (TACTiC) initiative.
The programme focuses on putting the latest WHO recommendations into practice while generating evidence to support their wider adoption in countries affected by the disease.
Tuberculosis remains the world’s deadliest infectious disease, with children continuing to account for a significant proportion of those affected.
According to the WHO’s 2026 Global Tuberculosis Report, half of children under five who developed TB in 2025 were missed by diagnosis and consequently did not access treatment. The report indicates that the situation has not improved compared with previous years.
MSF is now calling on governments, donors and international health partners to accelerate the introduction of the four-month regimen rather than limiting their efforts to adopting treatment policies, arguing that children should benefit from available medical advances without further delays.







